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The compound sodium phenylbutyrate (PB) has been used for reducing ammonia in
patients with urea cycle disorders and proposed as a treatment for disorders with
enhanced branched-chain amino acid (BCAA) levels, due to its effects on promoting
BCAA catabolism. In skeletal muscle cells, we hypothesised that PB would induce
muscle protein catabolismdue to forcing BCAAdegradation away frommuscle protein
synthesis and downregulating mechanistic target of rapamycin (mTOR). PB reduced
medium BCAA and branched-chain keto acid (BCKA) concentrations, while total cell
protein (−21%; P < 0.001 vs. control) and muscle protein synthesis (−25%; P < 0.001
vs. control; assessed by measurement of puromycin incorporation into polypeptides)
were decreased with PB. The regulator of anabolic pathways mTOR and its down-
stream components were impaired with PB treatment. The present results indicate
that accelerated BCAA catabolism using PB resulted in adverse effects related to
mTOR signalling and muscle protein metabolism, which may limit its application in
settings wheremuscle wasting is a risk.
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1 INTRODUCTION
The compound sodium phenylbutyrate (PB) has been successfully used
as an ammonia-lowering drug for patients with urea cycle disorders
(UCDs), whereby nitrogen is disposed of in the urine in the form
of phenylacetylglutamine (Brusilow, 1991). PB acts by scavenging
ammonia using muscle as a surrogate for other failing organs, for
example the liver. The therapeutic potential of PB has also been
investigated in a wide range of conditions, including Huntington’s
disease, type 2 diabetes, cancer and sickle cell disease (Camacho
et al., 2007; Collins et al., 1995; Gardian et al., 2005; Özcan et al.,
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2006). The exact mechanisms by which PB may exert beneficial
effects across a wide range of disorders remain unclear, although
one observed effect of PB treatment is decreased levels of end-
oplasmic reticulum (ER) stress (Kolb et al., 2015). Another observed
consequence of PB treatment relates to its effect on branched-
chain amino acid (BCAA) metabolism, where studies have reported
substantial decreases in circulating BCAA concentrations with PB
administration in patients with UCD (Scaglia, Carter, O’Brien, & Lee,
2004). PB, which is converted into the activemetabolite phenylacetate
in vivo, is conjugated with glutamine to form phenylacetylglutamine,
for excretion in the urine (Holeček, 2018). In patients with maple
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syrup urine disease, a disorder of BCAA metabolism that results
in elevations of BCAAs in plasma, PB reduced circulating BCAAs
and branched-chain α-keto acids (BCKAs), by increasing flux
through the BCKA dehydrogenase complex (Brunetti-Pierri et al.,
2011).
Given the critical roles of BCAAs in the regulation of muscle
protein metabolism, it is feasible that administration of PB will
result in depletion of extracellular BCAAs, leading to downstream
dysregulation of muscle protein synthesis (MPS) and/or breakdown,
which could question its effectiveness as a treatment under certain
conditions. Given the importance of BCAAs in essential processes,
their depletion with PB could feasibly have adverse effects on
the body, whereby such impairments in anabolic pathways could
potentially exacerbate declines in muscle function in conditions
already characterised by dysregulated protein metabolism, such as
diabetes and cancer. In support of this, prior in vitro studies have
demonstrated that PB treatment can result in muscle atrophy and
impaired differentiation in C2C12 myotubes (Brown et al., 2018),
but in contrast, did not blunt clenbuterol-induced muscle growth in
vivo. In another study, increased leucine oxidation and decreased
protein synthesis were observed in ex vivo incubated rat muscles
treated with PB (Holecek et al., 2017). However, again contrary
to these findings, in diabetic rats, long-term administration of PB
decreased ubiquitin proteasome-mediated protein degradation and
atrophy in muscle (Reddy et al., 2019). As such, the effects of PB on
muscle metabolism remain incompletely understood and in particular,
how BCAA catabolism impacts signalling by mechanistic target of
rapamycin (mTOR) – which is the molecular sensor of intracellular
BCAAs.
Thus, the aims of the present study were to investigate the impact
of PB on muscle protein metabolism. Using an in vitro murine skeletal
muscle cellmodel, we assessed the impact of PB treatment on lowering
extracellular BCAAs, and the subsequent effects on muscle protein
homeostasis. We hypothesised that accelerating the catabolism of
BCAA would result in a dysregulation of mTOR signalling and protein
synthesis, resulting in cell protein catabolism.
2 METHODS
2.1 C2C12 cell culture experiments
Murine C2C12 myoblasts (passage 6–8; ECACC, Salisbury, UK) were
cultured at 37◦C and 5%CO2 in Dulbecco’s modified Eagle medium/F-
12 (DMEM/F-12, cat. no. 21041033; Thermo Fisher Scientific,
Loughborough, UK) supplemented with 10% (v/v) fetal bovine serum
(FBS) and 1% (v/v) antibiotic-antimycotic solution (Sigma-Aldrich,
Dorset, UK). Cells were seeded onto six-well plates (Nunclon™ Delta;
Thermo Fisher Scientific) and when cells reached ∼90% confluency,
differentiation was induced by replacing the medium with DMEM
containing 2% (v/v) horse serum. Experiments were performed on
day 4–5 post-induction of differentiation, with a medium change
performed every 48 h.
New Findings
∙ What is the central question of this study?
The compound sodium phenylbutyrate (PB) has
been shown to promote branched-chain amino acid
(BCAA) catabolism, and as such has been proposed
as a treatment for disorders with enhanced BCAA
levels: does PB inducemuscle protein catabolismby
forcing BCAA degradation away from muscle
protein synthesis and mechanistic target of
rapamycin (mTOR) inhibition?
∙ What is themain finding and its importance?
Accelerated BCAA catabolism using PB resulted
in adverse effects related to mTOR signalling and
muscle protein metabolism in skeletal muscle cells,
which may limit its application in conditions where
muscle wasting is a risk.
Cells were treated at the point of a medium change (using normal
differentiation medium) with 10 mmol l–1 (in the range of previously
used doses, e.g., Brown et al., 2018; Holecek et al., 2017) sodium PB
for 6 or 24 h (n = 5–6 experimental/well replicates per treatment
group). At the end of each time point, culture medium was collected
and cells were harvested in homogenization buffer (50 mmol l–1 Tris–
HCl, pH7.5, 1 mmol l–1 EDTA, 1 mmol l–1 EGTA, 10 mmol l–1 β-
glycerophosphate, 50 mmol l–1 NaF and a complete protease inhibitor
cocktail tablet (Roche, West Sussex, UK)) for immunoblotting analysis
and measurement of intracellular amino acid concentrations (see
below). In separate experiments, cells were also harvested after 24 h
in 0.3 mol l–1 NaOH for measurement of total protein, RNA and
DNA. Trypan Blue staining and visual assessment was used to ensure
treatments were not causing widespread adverse effects on cell
viability. Cells were incubated with 0.4% (v/v) Trypan Blue for 1–2min,
thenwashedwithPBSandvisualisedunder a lightmicroscope.Viability
was assessedvisually, that is, non-viable cellswere stainedand live cells
unstained.
2.2 Measurement of medium and intracellular
amino acids and branched-chain α-keto acids
Cell culture medium (100 μl) with 10 μl internal standard (a
mix of stable isotopically labelled amino acids) added, or iso-
lated intracellular amino acids, was purified by passing through
H+ Dowex resin columns and eluting into 2 mol l–1 NH4OH
before being dried down. Amino acids were derivatised to their
tert-butyldimethylsilyl esters, and concentrations were determined
using GC-MS (Trace 1300-ISQ; Thermo Fisher Scientific) with a
standard curve of known concentrations. Intracellular amino acid
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concentrations were normalised against total cellular protein per
well (using values from protein quantification prior to western blot
analysis).
Medium concentrations of BCKAs (α-ketoisocaproic acid, KIC;
α-keto-β-methylvaleric acid, KMV; and α-ketoisovaleric acid, KIV)
were determined by mixing 100 μl of cell culture medium with α-
ketovaleric acid as internal standard, deproteinizing with ice-cold
ethanol and drying down under nitrogen. The BCKAs were derivatised
to quinoxalinol-tert-butyldimethylsilyl derivatives, and concentrations
were determined using GC-MS (Trace 1300-ISQ; Thermo Fisher
Scientific) with a standard curve of known concentrations of each
BCKA.
2.3 Measurement of muscle protein synthesis
Muscle protein synthesis was determined in the 6-h experiments using
the surface sensing of translation (SUnSET) technique (Schmidt et al.,
2009), which involves detection of the incorporation of puromycin
(a tyrosyl-tRNA analogue) into newly synthesised polypeptide chains.
Puromycin (0.5 μmol l–1 final concentration) was added to the cells
for the final 3 h of the 6-h experiment. Immunoblotting (see below)
was used to measure puromycin-labelled peptides with a monoclonal
puromycin antibody (12D10; EMDMillipore,Watford, UK).
2.4 Protein:DNA ratio assessments
Samples that were treated for 24 h with PB were harvested in
0.3 M NaOH for measurement of total alkaline-soluble protein, RNA
and DNA using the method described by Forsberg et al. (1991). In
brief, samples were incubated at 37◦C for 20 min and total protein
was quantified using a NanoDrop™ 2000 (Thermo Fisher Scientific).
Perchloric acid (1 mol l–1) was then added to each sample before
incubation at 4◦C for 30min. Following centrifugation, the supernatant
was quantified for RNA, then following removal of the supernatant,
2mol l–1 perchloric acidwas then added to the pellet and sampleswere
incubated at 70◦C for 1 h. Finally, DNA was quantified in the resultant
supernatant.
2.5 Western blot analysis
Samples were lysed by repeatedly passing through gel-loading pipette
tips and lysates were centrifuged at 13,000 g for 10 min at 4◦C.
Protein from each sample (total 10 μg) was loaded onto 12% Criterion
XT Bis-Tris gels (Bio-Rad Laboratories, Hemel Hempstead, UK) and
samples were electrophoresed at 200 V for 1 h. Transfer to poly-
vinylidene difluoride membrane was performed at 100 V for 45 min,
then membranes were blocked in 5% (w/v) milk for 1 h at room
temperature. Primary antibody incubation was carried out overnight
at 4◦C with the following primary antibodies: mTOR Ser2448 (cat.
no. 5536), ribosomal protein S6 kinase 1 (p70 S6K1) Thr389 (cat.
no. 9234), eukaryotic translation initiation factor 4E binding protein
1 (4E-BP1) Thr37/46 (cat. no. 2855) (from Cell Signaling Technology,
Danvers, MA, USA). After primary antibody incubations, membranes
were washed with 1× Tris-buffered saline–Tween and incubated with
anti-rabbit horseradish peroxidase (HRP)-conjugated secondary anti-
body (cat. no. 7074; Cell Signaling Technology; 1:2000 dilution) for 1 h
at room temperature. After further washing with TBS–Tween, bands
were detected using Chemiluminescent HRP substrate (EMD Milli-
pore, Watford, UK) with a Chemidoc XRS imaging system (Bio-Rad).
Coomassie Brilliant Blue staining of the membrane was used for total
protein normalisation and bands were quantified by densitometric
analysis using Image Lab software (version 6; Bio-Rad).
2.6 Statistical analyses
All statistical analyses were performed using GraphPad Prism 7
(GraphPad Software Inc., La Jolla, CA, USA). Descriptive statistics
were produced to confirm normal distribution (accepted if P > 0.05).
Data were analysed using Student’s unpaired t-test for two-group
comparisons, and where there were multiple time points, results were
analysed by two-way ANOVA with Tukey’s post hoc test to locate
specific differences. P< 0.05was considered as statistically significant.
All data are presented as box and whisker plots (where the median
is the horizontal line, interquartile range is the box, minimum and
maximum are the whiskers).
3 RESULTS
3.1 Amino acid and α-keto acid concentrations
with PB treatment in C2C12 myotubes
Treatment with 10 mmol l–1 PB caused a significant reduction in
medium leucine (mean± SEM 406± 2 vs. 459± 20 μmol l–1, P= 0.026
at 6 h; 423± 6 vs. 457± 6 μmol l–1, P= 0.0048 at 24 h), valine (417± 2
vs. 470 ± 20 μmol l–1, P = 0.027 at 6 h; 425 ± 4 vs. 468 ± 7 μmol l–1,
P = 0.0005 at 24 h) and isoleucine (374 ± 5 vs. 428 ± 22 μmol l–1,
P= 0.041 at 6 h; 391± 5 vs. 430± 7 μmol l–1, P= 0.0035 at 24 h) after
6 and 24 h, compared to untreated controls (Figure 1a–c). Treatment
with 10mmol l–1 PB also caused a significant reduction in mediumKIC
(46± 3 vs. 58± 2 μmol l–1, P= 0.017 vs. control (Ctl)), KMV (36± 2 vs.
45± 1 μmol l–1, P= 0.0064 vs. Ctl) and KIV (18± 1 vs. 22± 1 μmol l–1,
P = 0.039 vs. Ctl) at 6 h relative to the control group, which was no
different to control concentrations by 24 h (Figure 1d–f). For medium
BCAA andKIC, therewere no differences in concentrations between 6
and 24 h in either control or PB-treated cells, but there was a relative
increase in medium KIV (P = 0.02 vs. 6 h) and KMV (P = 0.026 vs. 6 h)
between time points with PB treatment (Figure 1e, f).
Intracellular amino acid concentrations were assessed following PB
treatment in C2C12 myotubes, normalised to cellular total protein.
Treatment with 10 mmol l–1 PB had no effect on valine concentrations
at 6 h, but there was a reduction in intracellular leucine (11 ± 0.3
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F IGURE 1 Medium branched-chain amino acid and α-keto acid concentrations in C2C12myotubes following phenylbutyrate (PB) treatment.
C2C12myotubes were treated for 6 and 24 hwith 10mmol l–1 PB (n= 5 per group). Mediumwas analysed for concentrations of branched-chain
amino acids: leucine (a), isoleucine (b) and valine (c); and α-keto acids: α-ketoisocaproic acid (KIC; d), α-keto-β-methylvaleric acid (KMV; e) and
α-ketoisovaleric acid (KIV; f). Data are presented as box andwhisker plots (median is horizontal line; interquartile range is box; minimum and
maximum are whiskers) and units are μmol l–1. *P< 0.05 vs. control (Ctl), **P< 0.01 vs. Ctl, ***P< 0.001 vs. Ctl. #P< 0.05 vs. 6 h
vs. 14 ± 0.7 μmol μg–1 protein, P = 0.0042) and isoleucine (5.4 ± 0.2
vs. 6.8 ± 0.4 μmol μg–1 protein, P = 0.017) at 6 h (Figure 2a–c)
compared to controls. After 24 h, intracellular BCAA concentrations
were no different from controls (Figure 2a–c). There were no
significant differences in intracellular amino acids across the time
points measured (Figure 2). Concentrations of intracellular glutamine
(87 ± 1.3 vs. 122 ± 2.7 μmol μg–1 protein, P < 0.0018), glutamate
(66 ± 3.7 vs. 124 ± 9.5 μmol μg–1 protein, P = 0.0005) and alanine
(13±0.6 vs. 17±1.8μmolμg–1 protein,P=0.036)were also decreased
after 6-h PB treatment (Figure 2d–f), relative to the control group,
and while both glutamine and glutamate showed sustained decreases
across all time points, by 24 h intracellular alanine levels were not
different from those of control cells (Figure 2f).
3.2 Protein, RNA and DNA content, and changes
in protein synthesis with PB treatment in C2C12
myotubes
To evaluate the impact of PB on muscle anabolic signalling and
aspects of cell size, total protein, RNA and DNA content was
measured following PB administration, as well as selected regulators
of anabolic pathways. Total alkaline-soluble protein, RNA and DNA
content per well were all decreased following 24-h PB treatment
(respectively 1177 ± 19 vs. 1496 ± 22 μg, P < 0.0001; 45.9 ± 0.9 vs.
64.1± 0.8 μg, P < 0.0001; and 17.3± 0.5 vs. 21.4 ± 0.5 μg, P < 0.0001;
Figure 3a–c) in comparison to controls. Protein synthesis, measured
by puromycin incorporation into cellular protein, was significantly
decreased following 6-h PB treatment (P= 0.0002 vs. Ctl; Figure 3d, e).
An absenceof stainingwithTrypanBlue after 24h confirmed therewas
no decrease in cell viability with PB treatment (Figure 3f).
In terms of anabolic signalling pathways, PB resulted in a decrease
in mTOR phosphorylation at 6 h compared with untreated cells
(0.5 ± 0.04-fold; P = 0.0024), which was no different from control by
24 h (Figure 4a). Phosphorylated p70 S6K1 (Thr389) was significantly
decreasedwith PB at both 6 h (P< 0.0001 vs. Ctl) and 24 h (P= 0.0002
vs. Ctl; Figure 4b). For both mTOR and p70 S6K1, there were relative
increases in phosphorylation in the PB-treated cells at 24 h versus 6 h
(both P < 0.0001 vs. 6 h; Figure 4a, b). Finally, phosphorylated 4E-BP1
(Thr37/46)was alsodecreasedat both timepoints (P=0.0052vs.Ctl at
6 h; P=0.0033 vs. Ctl at 24 h; Figure 4c)with PB, relative to the control
group.
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F IGURE 2 Intracellular amino acid concentrations in C2C12myotubes following phenylbutyrate (PB) treatment. C2C12myotubes were
treated for 6 and 24 hwith 10mmol l–1 PB (n= 5 per group). Cells were analysed for intracellular concentrations of selected amino acids: leucine
(a), isoleucine (b), valine (c), glutamine (d), glutamate (e) and alanine (f). Data are presented as box andwhisker plots (median is horizontal line;
interquartile range is box; minimum andmaximum are whiskers) and units are μmol μg–1 protein. *P< 0.05 vs. control (Ctl), **P< 0.01 vs. Ctl,
***P< 0.001 vs. Ctl
4 DISCUSSION
Administration of PB has been used as an ammonia-lowering drug
for patients with UCD (Brusilow, 1991), but depletion of circulating
BCAA has been observed in these patients (Scaglia et al., 2004), and
PB has directly been shown to activate the BCKA dehydrogenase
complex (Brunetti-Pierri et al., 2011). Given the importance of BCAAs
as critical substrates and regulators of MPS (Kimball & Jefferson,
2001), this effect of PB could have negative impacts on protein
metabolism in muscle. For certain conditions characterised by under-
lying dysregulation of protein metabolism such as diabetes and cancer,
these declines in BCAAs could potentially further negatively impact
on anabolic processes in muscle, exacerbating declines in muscle
function and health. It is important therefore to investigate the
molecular mechanisms by which PB exerts its effects on muscle,
where there is currently little insight available. We hypothesised
that increasing BCAA catabolism using the compound PB would
result in an mTOR-associated dysregulation of protein homeostasis,
resulting in cellular protein catabolism. We observed that while
murine C2C12 myotubes treated with PB had lowered medium
and cellular BCAA concentrations, prolonged treatment resulted in
impairments in protein metabolism, which appeared to be, at least
partly, due to reduced activity of mTOR-regulated anabolic signalling
andMPS.
During time-course experiments, treatment with the compound PB
(as expected from previous studies; Holecek et al., 2017) reduced
medium concentrations of BCAAs after 6 h post-treatment. BCKAs
were also decreased in the medium 6 h post-treatment, indicating
that intracellular BCAAs were being metabolised at least beyond
BCAA transaminase (BCAT), the first enzyme in the BCAA catabolism
pathway. Catabolism of the BCAAs also impacted other amino acids
intracellularly, with decreases in glutamine, glutamate and alanine
following 6-h treatment. Medium concentrations of glutamine and
glutamate also followed similar decreases with PB treatment (data not
shown). It has been proposed that PB results in depletion of glutamine,
through formation of phenylacetylglutamine (Holeček, 2018). Studies
have previously described that glutamine deficiency can have negative
impacts on muscle protein metabolism (Holecek & Sispera, 2014),
suggesting the declines in both cellular BCAA and glutamine may have
been responsible for the impairments in muscle protein metabolism
with PB administration. One limitation of the present study was that
we did not measure phenylacetate levels following PB treatment
and so cannot determine whether this conversion is required for
its activity. However, the observed changes in BCAA and cellular
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F IGURE 3 Total protein, RNA andDNA following PB treatment, and puromycin incorporation following PB treatment in C2C12myotubes.
C2C12myotubes were treated for 24 hwith 10mmol l–1 PB (n= 6 per group). (a–c) Cells were analysed for total protein (a), RNA (b) and DNA (c)
content. (d, e) In separate experiments, C2C12myotubes were treated for 6 hwith or without PB, with puromycin being added for the final 3 h.
Cells were analysed for puromycin labelling of cellular polypeptides. Data are presented as box andwhisker plots (median is horizontal line;
interquartile range is box; minimum andmaximum are whiskers). (f) Cells were stained after 24 hwith Trypan Blue to assess changes in cell
viability. Scale bars represent 100 μm. ***P< 0.001 vs. control (Ctl). CBB, Coomassie Brilliant Blue
F IGURE 4 Anabolic-related signalling
changes in C2C12myotubes following
phenylbutyrate (PB) treatment. C2C12
myotubes were treated for 6 and 24 hwith
10mmol l–1 PB (n= 5 per group). Cells were
analysed for phosphorylation of mechanistic
target of rapamycin (mTOR; Ser2448) (a),
ribosomal protein S6 kinase 1 (p70 S6K1;
Thr389) (b) and eukaryotic translation
initiation factor 4E-binding protein 1 (4E-BP1;
Thr37/46) (c). Data are presented as box and
whisker plots (median is horizontal line;
interquartile range is box; minimum and
maximum are whiskers). **P< 0.01 vs. control
(Ctl), ***P< 0.001 vs. Ctl. ###P< 0.001 vs. 6 h.
RAU, relative arbitrary units
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glutamine support the chemistry of PB action in our present model.
Overall, the model used in the present study produced the expected
effects on BCAA catabolism, allowing us to directly assess the impact
of decreased cellularBCAAsandglutamineon the regulationof protein
metabolism in skeletal muscle cells.
Prolonged PB treatment (24 h) also resulted in decreased total
cellular protein with the dose of PB used (10 mmol l–1), which
could have reflected not only reduced anabolism but also potentially
a protein catabolic response to the compound. There were also
reductions in total cellular RNA and DNA with PB treatment,
suggesting myotube loss may have occurred. Previous studies have
reported atrophic effects of PB treatment in muscle (Brown et al.,
2018), though whether this is a direct result of the depletion in
extracellular BCAAs remains to be determined. Since there were
impairments in mTOR activity with PB, it is feasible that additional
signalling pathways were altered, including induction of autophagy,
since mTOR is a key regulator of autophagy regulation via alteration
of unc-51-like kinase 1/2 (Ulk1/2) kinase activity (Alers et al., 2012).
The compound PB has also been shown to influence other biological
pathways, including modulation of ER stress and inhibition of histone
deacetylases (Khan et al., 2017). Future work should aim to uncover
whether targeting BCAA catabolism using different approaches (e.g.
using an inhibitor of BCKA dehydrogenase kinase; Zhou et al., 2019),
would result in the observed adverse effects on protein metabolism,
as well as explore the downstream impact of mTOR inhibition on
activation of catabolic processes such as autophagy.
In terms of the effects of PB on MPS (measured in this study by
assessing labelling of cellular protein with puromycin for the final 3 h
of treatment), therewas a significant declinewith PB. This is consistent
with previous observations (Brown et al., 2018; Holecek et al., 2017),
and whether these changes are a direct result of reduced BCAA levels
(i.e. secondary to reduced amino acid sensing from substrate shortage)
remains to be evaluated. Future work could focus on inhibiting BCAT
activity in cells to examine how this might alleviate the inhibition on
MPS, although recent studies have suggested specific knockdown of
BCAT2 inhibited myotube formation in vitro (Dhanani et al., 2019).
We also assessed molecular markers that could be responsible for
mediating these impairments in MPS; observing decreases in mTOR
Ser2448 phosphorylation with 6-h PB treatment, as well as reduced
phosphorylation (i.e. reduced activation) of downstream regulators of
translation initiation (p70 S6K1 and 4E-BP1), whichwere still impaired
after 24 h. Multiple amino acid-sensing proteins have been identified,
including the recombination-activating gene (RAG) and Sestrin family
of proteins, and proposed as important upstream regulators of mTOR
activity (Shimobayashi & Hall, 2016). It is possible that one or more of
these amino acid sensing pathways were responsible for the impaired
mTOR activation in the present study, secondary to BCAA and/or
glutamine depletion by PB.
In conclusion, we demonstrate that incubation with PB accelerated
in vitro BCAA catabolism in muscle cells, and sustained treatment with
PB resulted in impairments in protein metabolism, at least partly, due
to an impairment inmTOR-signalling andMPS. The findings contribute
further insight into the impact of PB on muscle protein balance and
suggest that adverse effects on muscle protein metabolism may be a
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